The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 28, 2019
Filed:
Apr. 20, 2015
Applicant:
Xuanzhu Pharma Co., Ltd., Jinan, CN;
Inventor:
Frank Wu, Jinan, CN;
Assignee:
Xuanzhu Pharma Co., Ltd., Jinan, Shandong, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); C07D 213/74 (2006.01); C07D 239/48 (2006.01); C07D 403/04 (2006.01); C07D 405/14 (2006.01); C07D 451/02 (2006.01); C07D 487/10 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 213/74 (2013.01); C07D 239/48 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); C07D 451/02 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01);
Abstract
Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.